Viyash Scientific financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹946cr+114.4% on Q1 FY26
Net profit
₹79.3cr+351.3% on Q1 FY26
EBITDA margin
18.9%+7.0 pts on Q1 FY26
EPS
₹1.51+164.9% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue946441+114.4%
EBITDA17852.2+241.8%
EBITDA margin18.9%11.8%+7.0 pts
Profit before tax11225.5+340.5%
Net profit79.317.6+351.3%
EPS₹1.51₹0.57+164.9%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹946 crNet profit₹79.3 crNet margin8.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
9,916————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
25625662.767.441.6
20420465.956.450.4
436436446451398
10,300————
3,1493,4201,5511,3701,421
—+120.5%+13.3%−3.6%—
59465316261.412.0
18.9%19.1%10.4%4.5%0.8%
39841995.3−0.1−43.7
21422532.3−29.6−122
6.8%6.6%2.1%−2.2%−8.6%
₹3.92₹4.06₹0.50−₹0.82−₹2.77
—+710.2%+161.0%+70.4%—
—32383.430.616.8
—−135−39.1−30.8−86.2
18818844.3−0.2−69.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIYASH₹227.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹9,916 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————9,916.5
- Cash, Equiv & ST Investments41.667.462.7255.8255.8
+ Minority Interest50.456.465.9203.7203.7
+ Total Debt397.9451.3446.4435.8435.8
Enterprise Value————10,300.2
Revenue1,420.91,369.71,551.43,420.33,148.7
Growth %, YoY—-3.6+13.3+120.5—
EBITDA12.061.4161.8652.5593.9
Margin %0.844.4810.4319.0818.86
EBIT-43.7-0.195.3418.9397.8
Net Income-122.0-29.632.3224.7213.8
Margin %-8.58-2.162.086.576.79
EPS, Adj (current shares)-2.77-0.820.504.063.92
Growth %, YoY—+70.4+161.0+710.2—
Cash from Operations16.830.683.4322.9—
Capital Expenditures-86.2-30.8-39.1-134.7—
Free Cash Flow-69.4-0.244.3188.2188.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Viyash Scientific financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Viyash Scientific (NSE: VIYASH) had a market capitalisation of ₹9,809 crore at the 29 October 2026 close (₹224.55 a share), a PE ratio of 57.3 on the last four quarters' profit and a price-to-book ratio of 3.37. In FY26 its consolidated net profit attributable to shareholders was ₹177 crore on revenue of ₹3,420 crore; in Q1 FY27 (April–June 2026) it was ₹65.9 crore, up 360.3% year on year. Its debt-to-equity ratio was 0.14 on 31 March 2026. Promoters held 49.24% of the shares on 30 September 2026.

Share price used
₹224.55 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Viyash Scientific at a glance · consolidated

Market cap
₹9,809 Crat ₹224.55 · 29 Oct close
PE ratio (last 4 quarters)
57.355.3 on FY26 profit
Price to book (PB)
3.37book value ₹66.64 a share
ROE (FY26)
9.8%+6.6 pts vs FY25ROCE 17.5%
Debt to equity
0.14net debt ₹166 Cr
Promoter holding
49.24%−12.1 pts vs 30 Jun 202630 September 2026
Net worth
₹2,911 Cr+313.2% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹188 Cr+325.1% vs FY25
EPS (FY26)
₹4.09

Questions

What is the Viyash Scientific PE ratio today?

Viyash Scientific's PE ratio is 57.3 at the 29 October 2026 close (₹224.55 a share): a market capitalisation of ₹9,809 crore divided by consolidated net profit attributable to shareholders of ₹171 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹177 crore) it is 55.3. These four quarters include net exceptional items of −₹43 crore (one-off charges reported separately), so the ratio on recurring profit would differ.

What is the Viyash Scientific PB ratio (price to book value)?

Viyash Scientific's price-to-book (PB) ratio is 3.37 at the 29 October 2026 close: a market capitalisation of ₹9,809 crore divided by shareholders' equity (book value) of ₹2,911 crore on 31 March 2026. That is a book value of ₹66.64 per share against a share price of ₹224.55.

What is the Viyash Scientific ROE and ROCE?

In FY26, Viyash Scientific's return on equity (ROE) was 9.8% and its return on capital employed (ROCE) was 17.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.2% and ROCE 9.5%.

What is the Viyash Scientific market cap?

Viyash Scientific's market capitalisation was ₹9,809 crore at the 29 October 2026 close: 43.69 crore shares at ₹224.55 each.

Is Viyash Scientific debt free?

No. Viyash Scientific had borrowings of ₹436 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.14. Its cash and current investments were ₹270 crore, so its net debt was ₹166 crore.

What is the Viyash Scientific EPS?

Viyash Scientific's basic earnings per share (EPS) were ₹4.09 in FY26.

What is the Viyash Scientific debt to equity ratio?

Viyash Scientific's debt-to-equity ratio was 0.14 on 31 March 2026: borrowings of ₹436 crore against total equity of ₹3,115 crore. A year earlier, on 31 March 2025, it was 0.58.

What is the Viyash Scientific net worth?

Viyash Scientific's net worth — shareholders' equity in its consolidated balance sheet — was ₹2,911 crore on 31 March 2026, up 313.2% from ₹704 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹9,809 crore at the 29 October 2026 close.

What is the Viyash Scientific book value per share?

Viyash Scientific's book value per share was ₹66.64 on 31 March 2026: shareholders' equity of ₹2,911 crore divided by the 43.69 crore shares in issue. The share price at the 29 October 2026 close was ₹224.55.

What is the Viyash Scientific promoter holding?

Promoters held 49.24% of Viyash Scientific on 30 September 2026, down 12.07 percentage points from 61.31% the previous quarter and down 3.09 percentage points from 52.33% a year earlier, according to the shareholding pattern filed with NSE.

What is the Viyash Scientific free cash flow?

In FY26, Viyash Scientific generated ₹323 crore of cash from operations and spent ₹135 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹188 crore. In FY25 it was ₹44.3 crore.

What are the Viyash Scientific latest quarterly results?

Viyash Scientific's latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit attributable to shareholders ₹65.9 crore, up 360.3% from ₹14.3 crore in Q1 FY26; revenue from operations ₹946 crore, up 114.4% year on year.

What is the Viyash Scientific shareholding pattern?

On 30 September 2026, Viyash Scientific's shares were held by promoters 49.24%, foreign portfolio investors (FII/FPI) 2.60%, domestic institutions (DII) 8.30% (including mutual funds at 7.13%) and retail and other non-institutional investors 39.76%. Over the year, FII holding was down 3.31 percentage points from 5.91% and DII holding was down 4.61 percentage points from 12.91%.

How does the Viyash Scientific PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Viyash Scientific's PE ratio is 55.3, the highest of the four: Aarti Drugs 21.0, Yatharth Hospital & Trauma Care Services 52.2 and Thyrocare Technologies 50.3, a peer average of 41.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Viyash Scientific vs Aarti Drugs: how do they compare?

In FY26, Viyash Scientific earned net profit attributable to shareholders of ₹177 crore on revenue of ₹3,420 crore, against ₹195 crore on ₹2,565 crore for Aarti Drugs. Viyash Scientific's operating margin was 12.3% (Aarti Drugs 9.4%) and its return on equity 9.8% (Aarti Drugs 13.4%). At the 29 October 2026 close, Viyash Scientific's market capitalisation was ₹9,809 crore against ₹4,098 crore for Aarti Drugs, and its PE ratio on FY26 profit 55.3 against 21.0.

What is the Viyash Scientific revenue and profit in FY26?

In FY26 (April 2025–March 2026), Viyash Scientific's consolidated net profit attributable to shareholders was ₹177 crore, up 710.2% from ₹21.9 crore in FY25, on revenue from operations of ₹3,420 crore (up 120.5%).

When are the Viyash Scientific next results?

Viyash Scientific has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Viyash Scientific compare with its peers?

On FY26 consolidated figures, against Aarti Drugs, Yatharth Hospital & Trauma Care Services and Thyrocare Technologies: Viyash Scientific's operating margin of 12.3% is the third highest of the four (Aarti Drugs 9.4%, Yatharth Hospital & Trauma Care Services 16.9%, Thyrocare Technologies 24.5%; peer average 17.0%); its return on equity of 9.8% is the lowest of the four (Aarti Drugs 13.4%, Yatharth Hospital & Trauma Care Services 10.0%, Thyrocare Technologies 28.8%; peer average 17.4%); its revenue growth over three years of 34.0% a year is the second highest of the four (Aarti Drugs −1.9% a year, Yatharth Hospital & Trauma Care Services 48.1% a year, Thyrocare Technologies 16.3% a year; peer average 20.8% a year).

Where do these Viyash Scientific figures come from?

From Viyash Scientific's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.